Every 8-K that Tactile Systems Technology, Inc. (TCMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TCMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCMD filings page.
Tactile Systems Technology, Inc. reported strong results for the quarter ended June 30, 2026. Total revenue rose 9% to $85.7 million from $78.9 million a year earlier, driven by a 12% increase in lymphedema product revenue, partially offset by lower airway clearance sales tied to temporary inventory dynamics around the next-generation AffloVest launch.
Gross profit increased to $65.3 million, with gross margin improving to 76% from 75%. Operating income rose to $6.8 million, and net income grew to $7.8 million, or $0.34 per diluted share, compared to $3.2 million, or $0.14 per share, in the prior-year quarter. Adjusted EBITDA climbed to $11.4 million, up 49% from $7.7 million.
For the first six months of 2026, revenue increased 15% to $161.0 million, with net income of $6.0 million and Adjusted EBITDA of $15.1 million, more than doubling year over year. The company ended June 30, 2026 with $69.9 million in cash and no outstanding borrowings, after repurchasing $5.3 million of stock in the quarter. Full-year 2026 revenue guidance was narrowed to $360–$366 million (9–11% growth), while Adjusted EBITDA guidance was maintained at $49–$51 million.
Tactile Systems Technology, Inc. entered into an exclusive U.S. distribution agreement with ElastiMed, Inc. to distribute the MyoSleeve™ wearable, non-pneumatic compression device to Department of Veterans Affairs and Department of Defense patients across the United States. MyoSleeve, which has U.S. Food and Drug Administration 510(k) clearance for treating chronic swelling conditions, is a discreet, battery-powered lower-leg device designed for earlier stages of disease and as a complement to traditional pneumatic compression therapy.
Under the agreement, Tactile Systems paid $3 million upfront to ElastiMed, obtained exclusive distribution rights within VA and DoD systems, and committed to minimum purchase, marketing, and sales promotion obligations while leveraging its existing sales and patient-support infrastructure to commercialize MyoSleeve.
Tactile Systems Technology, Inc. held its 2026 annual meeting on May 6, 2026, where stockholders elected all nine director nominees for terms running until the 2027 annual meeting. Each nominee received over 15.3 million votes in favor, with relatively few votes withheld and 3,011,527 broker non-votes for each.
Stockholders also ratified the selection of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026, with 18,499,882 votes for and 126,747 against. In an advisory vote, stockholders approved executive compensation, and they approved an amendment to the Amended and Restated Certificate of Incorporation so directors may be removed in a manner consistent with Delaware law.
Tactile Systems Technology, Inc. reported a strong first quarter of 2026, with total revenue rising 23% to $75.3 million from $61.3 million a year earlier. Growth was broad-based, as lymphedema product revenue increased to $62.2 million and airway clearance revenue rose to $13.0 million, each maintaining 83% and 17% of total sales.
Gross profit grew 27% to $57.6 million and gross margin improved to 76.5%. Operating loss narrowed to $1.5 million and net loss improved to $1.8 million, or $0.08 per diluted share. Adjusted EBITDA swung to a positive $3.7 million from a small loss, helped by higher revenue and operating leverage.
As of March 31, 2026, the company held $75.0 million in cash with no borrowings and repurchased $1.1 million of stock. Management raised its 2026 revenue outlook to $360–$368 million, implying 9%–12% growth over 2025, while maintaining adjusted EBITDA guidance of $49–$51 million. The quarter also reflected integration of the LymphaTech acquisition and ongoing investment in R&D and commercialization.
Tactile Systems Technology, Inc. appointed Andrea A. Pearson to its board of directors, effective March 9, 2026, and set the board size at nine members. She will serve on the Compliance and Reimbursement Committee and the Nominating and Corporate Governance Committee.
For her board service, Ms. Pearson will receive restricted stock units valued at a pro rata portion of $155,000, granted March 9, 2026, vesting on the date of the Company’s 2026 annual stockholders’ meeting if she remains a director. She will also receive annual cash retainers of $50,000 for board service and $5,000 each for her roles on the two committees, all prorated for her first year.
Tactile Systems Technology reported strong fourth quarter and full-year 2025 results and announced a strategic acquisition. Fourth quarter revenue rose 21% to $103.6 million, with operating income up to $18.8 million and net income of $10.6 million, or $0.46 per diluted share. Full-year 2025 revenue grew 12% to $329.5 million, driven by 7% growth in lymphedema products and 52% growth in airway clearance products. Net income increased to $19.1 million and Adjusted EBITDA rose to $44.8 million, reflecting improved profitability.
The company ended 2025 with $83.4 million in cash and no debt after repaying $26.3 million of term loan borrowings and repurchasing $26.5 million of stock. For 2026, it guides revenue to $357–$365 million and Adjusted EBITDA to $49–$51 million, implying continued growth. Separately, Tactile Medical acquired LymphaTech Inc. for an upfront cash payment of $6.8 million plus potential milestone-based consideration, adding a 3D digital measurement platform to deepen its lymphedema solutions portfolio.
Tactile Systems Technology, Inc. (TCMD) announced a new share repurchase program authorizing the company to buy back up to $25 million of its common stock. Repurchases may occur in the open market or through privately negotiated transactions. The program became effective on November 3, 2025 and expires on November 3, 2027.
The company stated it currently expects to fund the program with existing cash and future cash flows. TCMD also furnished a press release disclosing results of operations and financial condition for its most recently completed fiscal quarter as Exhibit 99.1, which, under applicable rules, is not deemed filed.